With Plasma BioMed and Sichuan Kelun Botai Biomedical Co., Ltd. focusing on innovative drug development (" Columbotech" announced the global strategic cooperation, and Platinum Pharmaceuticals will receive the exclusive development, production and commercialization of PD-L1 antibody drug A167, which is in the second phase of clinical use of Columbusta, globally (except Greater China). license. The potential value of this agreement is more than $350 million and sales commission. At the same time, the two sides also reached an agreement on the development of a combination of A167 and other drugs on a global scale; the two parties will license each other's non-competitive development rights in combination with A167 in their respective regions.

A167 is a tumor immunoglobulin drug candidate developed by Columbotech. It can be used to treat a variety of hematological tumors and solid tumors by inhibiting PD-L1 and stimulating the patient's own immune system to attack tumor cells. A167 has already conducted a number of Phase I and Phase II clinical trials for lymphoma and solid tumors in China.

"The PD-L1 antibody drug in the field of tumor immunity has been verified in many clinical trials and has become a key layout for pharmaceutical companies in the field of oncology. We are very pleased to cooperate with Columbotech in depth to obtain A167 global development outside Greater China. And exclusive licensing for commercialization." Dr. Wang Jinsong, founder, chairman and CEO of Platinum Pharmaceuticals, said, "Explore the combination of immunotherapy (such as PD-1/PD-L1 mAb) with other drugs to find a suitable tumor. more effective safety combination therapy, is currently the world anti-tumor drug research innovation and breakthrough point. pharmaceuticals and platinum being synchronized with a series of research and development of innovative drugs in combination with A167, A167 in the future can be carried out independently or in cooperation in the field of global The combination drug research provides a better drug selection plan for the treatment of various malignant tumors. This cooperation with Columbotech will accelerate the globalization of the clinical product line of platinum medicine, and it is the innovation and cooperation strategy of platinum medicine. The important composition."

"At the beginning of this year, we reached an agreement with Platinum Pharmaceuticals to jointly discover, develop and commercialize innovative human-targeted antibody drugs based on Platinum's leading antibody discovery platform. The two sides are carrying out major diseases such as cancer and autoimmunity. The early antibody development project for multiple targets is progressing well." Dr. Xue Wei, CEO of Columbotai, said, "We are very pleased to be able to establish a strategic partnership with Platinum Pharmaceuticals to establish clinical products. Columbotech is immune to tumors. The treatment is a series of innovative drugs, A167 is one of the key projects. The cooperation comes from the recognition of each other's research and development capabilities and experience, and Platinum Pharmaceutical has extensive global clinical research experience. Through cooperation, we will accelerate the extensive A167-based development. Global clinical development, especially the development and commercialization of joint drugs. We are looking forward to this cooperation."

Based on this partnership agreement, Columbotech will receive a down payment and receive milestone payments in advance of pre-agreed clinical development, registration and commercialization goals, totaling more than $350 million; Net sales share. And Platinum Pharmaceuticals will lead the clinical development and commercialization of A167 outside China, as well as production and management rights. The two companies will share all relevant research data to support the clinical and registration of single and combined drugs in their respective fields.

 --------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.